Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 by William New, Intellectual Property Watch 1 Comment Share this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) IP-Watch and its Health Policy Watch are non-profit independent news services and depend on subscriptions. To access all of our content, please subscribe here. You may also offer additional support with your subscription, or donate. A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy. The letter argues that the company had negotiated in good faith, that there were no access issues in Colombia, and hints that a compulsory licence might not be in line with the “rule of law.” But it does not explain how that could be, since countries have the right to issue such licences under international trade rules. Novartis also argues that even a “declaration of public interest” of Glivec could harm Colombia’s reputation. With prices of some US$ 15,000 per patient per year, Colombia after this letter was received took the step aimed at “price reduction,” but stopped short of a compulsory licence, Public Eye said. The full press release from Public Eye is reprinted below. The letter is scanned in the text. Glivec in Colombia: new leaked letter from Novartis attests to pressure at highest level 5. February 2018 A new leaked letter signed by the CEO of Novartis himself sheds additional light on the aggressive power play carried out by the Swiss pharma giant against the Colombian authorities to prevent a compulsory license* being issued for its leukemia drug Glivec (imatinib). This letter to the Presidency of Colombia, dated 8th June 2016, comes in addition to previously leaked letters to Colombian authorities that had already demonstrated Novartis’ efforts to avoid a compulsory license and any resulting reduction in the price of its blockbuster drug. It came just a week before Colombian Health Minister, Alejandro Gaviria, passed a hotly anticipated resolution to declare Glivec of public interest (Resolution 2475 of 2016). Under Colombian law, a declaration of public interest (DPI) can be a step towards a compulsory license. This letter can be seen as a further attempt by Novartis’ CEO to undermine legitimate decisions made by a sovereign state to protect its public health. In addition to the threat of international investment arbitration (or ISDS) made by Novartis in spring 2016, this letter undoubtedly had a direct influence on the content of the resolution mentioned above. As a result of this pressure, Resolution 2475 issued on 14th June 2016 focused only on price reduction, leaving aside the issue of a compulsory license. In 2016, Glivec was marketed in Colombia at a price of approximately CHF 15,000 per patient per year, almost twice the average annual income in Colombia. According to figures from the Health Ministry, sales of Glivec in Colombia in 2014 accounted for 0.2% of the net global sales of the product for that year. Since its launch, Glivec has generated over CHF 50 billion in global revenue for Novartis. The economic prospects are therefore irrelevant in this case – the matter is highly political. This additional leaked document reveals yet another side to the multi-pronged attack that Novartis has launched on sovereign countries that use legitimate legal instruments such as compulsory licenses, for fear that they might set a precedent. Also see the article published on 04/02/2018 in the Sonntagszeitung (PDF, 636 KB) Background: *A compulsory license is a legal and legitimate mechanism laid down in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization (WTO), which was reaffirmed in the ministerial Doha Declaration on TRIPS & Public Health (2001) and, most recently, by a landmark report of the UN High-Level Panel on Access to Medicines, co-chaired by former Swiss President Ruth Dreifuss (2016). A compulsory license allows a government to restore competition in a monopoly market despite a patent, without the authorization of the patent-holder. It is part of several policy-space mechanisms also called ‘TRIPS flexibilities’. According to the WTO, each member has the right to grant compulsory licenses, and the freedom to determine the grounds upon which such licenses are granted. Image Credits: – Flickr – European Patent Office Share this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related William New may be reached at firstname.lastname@example.org."Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.